Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 78 clinical trials
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study

anticoagulants
apixaban
rivaroxaban
anticoagulation therapy
vitamin k antagonist
  • 35 views
  • 22 Jan, 2021
  • 25 locations
The ARIES HeartMate 3 Pump IDE Study

Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K

aspirin
heart failure
  • 5 views
  • 07 Mar, 2021
  • 30 locations
CHAMPION-AF Clinical Trial

The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients

  • 0 views
  • 17 Feb, 2021
  • 15 locations
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

stroke (CHA2DS2-VASc Score 2) as well as high risk of bleeding as compared to best medical care (including a [non-vitamin K] oral anticoagulant [(N)OAC] when eligible).

warfarin
phenprocoumon
anticoagulants
apixaban
left atrial appendage closure
  • 13 views
  • 23 Jan, 2021
  • 32 locations
TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

This study will compare early with late start of treatment with Non-vitamin K oral anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation; it is a registry

anticoagulants
fibrillation
anticoagulation therapy
stroke
noac
  • 52 views
  • 24 Jan, 2021
  • 57 locations
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

(atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral

electrocardiogram
anticoagulants
fibrillation
apixaban
stroke
  • 42 views
  • 19 Feb, 2021
  • 140 locations
Oral Anticoagulation in Haemodialysis Patients

Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the

vitamins
  • 3 views
  • 25 Jan, 2021
  • 39 locations
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation

> Primary Objective: To determine the optimal time to initiate anticoagulation with a Non-Vitamin K Oral Anticoagulant (NOAC) after ischemic stroke in patients with non-valvular atrial fibrillation

ischemic stroke
deficit
anticoagulants
atrial fibrillation
thrombolytic
  • 132 views
  • 24 Jan, 2021
  • 15 locations
Dabigatran for Mitral Stenosis Atrial Fibrillation

thromboembolism due to the formation and embolism of left atrial thrombi. Current international guidelines recommend non-vitamin K oral anticoagulants (NOACs) for stroke prevention amongst these patients with non

  • 0 views
  • 28 Jan, 2021
  • 1 location
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with

anticoagulant
anticoagulants
renal function test
rivaroxaban
renal failure
  • 5 views
  • 26 Jan, 2021
  • 39 locations